Expression of the inhibitory Fc gamma receptor IIB ( FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy ( SAKK 35/98).

MLA

Lee, Chern Siang, et al. “Expression of the Inhibitory Fc Gamma Receptor IIB ( FCGR2B, CD32B) on Follicular Lymphoma Cells Lowers the Response Rate to Rituximab Monotherapy ( SAKK 35/98).” British Journal of Haematology, vol. 168, no. 1, Jan. 2015, pp. 145–48. EBSCOhost, https://doi.org/10.1111/bjh.13071.

APA

Lee, C. S., Ashton, K. M., Cogliatti, S., Rondeau, S., Schmitz, S. H., Ghielmini, M., Cragg, M. S., & Johnson, P. (2015). Expression of the inhibitory Fc gamma receptor IIB ( FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy ( SAKK 35/98). British Journal of Haematology, 168(1), 145–148. https://doi.org/10.1111/bjh.13071

Chicago

Lee, Chern Siang, Key, Margaret Ashton, Sergio Cogliatti, Stephanie Rondeau, Shu‐Fang Hsu Schmitz, Michele Ghielmini, Mark S Cragg, and Peter Johnson. 2015. “Expression of the Inhibitory Fc Gamma Receptor IIB ( FCGR2B, CD32B) on Follicular Lymphoma Cells Lowers the Response Rate to Rituximab Monotherapy ( SAKK 35/98).” British Journal of Haematology 168 (1): 145–48. doi:10.1111/bjh.13071.